Next report date
Report period
Q2 2024
EPS estimate
0.81SEK
Revenue estimate
5.08 BSEK
6.4SEK
2.41 BSEK
22.12 BSEK
181.40 M
About SWEDISH ORPHAN BIOVITRUM AB
Sector
CEO
Guido Oelkers
Headquarters
Solna
Website
Employees (FY)
1.77 K
Founded
2001
ISIN
SE0000872095
FIGI
BBG007R9HLM6
Swedish Orphan Biovitrum AB engages in the research, development, manufacture, and sale of pharmaceuticals. It operates through the Haematology, Immunology, and Specialty Care segments. The Haemotology segment focuses on haemophilia medicines Elocta and Alprolix. The immunology segment offers treatment for serious, disabling, and life-threatening diseases. The Specialty Care segment specializes in the treatment of genetic and metabolic diseases. The company was founded in 2001 and is headquartered in Solna, Sweden.
Trade directly on the supercharts through our supported, fully-verified and user-reviewed brokers.
Frequently Asked Questions
The current price of 0MTD is 282.4 SEK — it has decreased by 1.09% in the past 24 hours.
Depending on the exchange, the stock ticker may vary. For instance, on LSIN exchange SWEDISH ORPHAN BIOVITRUM AB NPV stocks are traded under the ticker 0MTD.
SWEDISH ORPHAN BIOVITRUM AB NPV is going to release the next earnings report on Jul 16, 2024. Keep track of upcoming events with our Earnings Calendar.
0MTD stock is 1.10% volatile and has beta coefficient of 0.67. Check out the list of the most volatile stocks — is SWEDISH ORPHAN BIOVITRUM AB NPV there?
0MTD earnings for the last quarter are 3.02 SEK per share, whereas the estimation was 3.58 SEK resulting in a −15.70% surprise. The estimated earnings for the next quarter are 2.34 SEK per share. See more details about SWEDISH ORPHAN BIOVITRUM AB NPV earnings.
SWEDISH ORPHAN BIOVITRUM AB NPV revenue for the last quarter amounts to 6.84 B SEK despite the estimated figure of 6.80 B SEK. In the next quarter revenue is expected to reach 5.69 B SEK.
Yes, you can track SWEDISH ORPHAN BIOVITRUM AB NPV financials in yearly and quarterly reports right on TradingView.
0MTD stock has risen by 4.25% compared to the previous week, the month change is a 8.08% rise, over the last year SWEDISH ORPHAN BIOVITRUM AB NPV has showed a 17.56% increase.
0MTD net income for the last quarter is 800.00 M SEK, while the quarter before that showed 1.03 B SEK of net income which accounts for −22.03% change. Track more SWEDISH ORPHAN BIOVITRUM AB NPV financial stats to get the full picture.
Today SWEDISH ORPHAN BIOVITRUM AB NPV has the market capitalization of 97.00 B, it has increased by 1.70% over the last week.
No, 0MTD doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.
Like other stocks, 0MTD shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade SWEDISH ORPHAN BIOVITRUM AB NPV stock right from TradingView charts — choose your broker and connect to your account.
As of May 2, 2024, the company has 1.77 K employees. See our rating of the largest employees — is SWEDISH ORPHAN BIOVITRUM AB NPV on this list?
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So SWEDISH ORPHAN BIOVITRUM AB NPV technincal analysis shows the buy rating today, and its 1 week rating is buy. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating SWEDISH ORPHAN BIOVITRUM AB NPV stock shows the buy signal. See more of SWEDISH ORPHAN BIOVITRUM AB NPV technicals for a more comprehensive analysis.
If you're still not sure, try looking for inspiration in our curated watchlists.
If you're still not sure, try looking for inspiration in our curated watchlists.
We've gathered analysts' opinions on SWEDISH ORPHAN BIOVITRUM AB NPV future price: according to them, 0MTD price has a max estimate of 370.00 SEK and a min estimate of 285.00 SEK. Read a more detailed SWEDISH ORPHAN BIOVITRUM AB NPV forecast: see what analysts think of SWEDISH ORPHAN BIOVITRUM AB NPV and suggest that you do with its stocks.
EBITDA measures a company's operating performance, its growth signifies an improvement in the efficiency of a company. SWEDISH ORPHAN BIOVITRUM AB NPV EBITDA is 7.63 B SEK, and current EBITDA margin is 35.37%. See more stats in SWEDISH ORPHAN BIOVITRUM AB NPV financial statements.